# Seminar 17: Psychiatric Emergencies

## Psychiatry Clerkship

---

## Learning Objectives

By the end of this seminar, students will be able to:

1. Conduct a structured suicide risk assessment including identification of risk factors, protective factors, and warning signs with stratification into clinical action levels
2. Develop a safety plan and determine the appropriate level of care for suicidal patients including voluntary and involuntary hospitalization criteria
3. Assess and manage acute agitation through verbal de-escalation techniques and pharmacological interventions using a stepwise approach
4. Recognize and treat neuroleptic malignant syndrome and serotonin syndrome as life-threatening pharmacological emergencies
5. Evaluate and manage catatonia including the diagnostic approach and use of benzodiazepine challenge and electroconvulsive therapy
6. Apply involuntary treatment criteria and understand the legal framework governing psychiatric holds and capacity determinations

---

## Seminar Outline

### Section 1: Suicide Risk Assessment Framework

Suicide represents one of the most critical clinical challenges in psychiatry, with approximately 48,000 deaths by suicide annually in the United States, making it the tenth leading cause of death overall and the second leading cause among individuals aged ten to thirty-four. A systematic approach to suicide risk assessment is essential because clinical intuition alone is insufficient to predict this low-base-rate event. The assessment must integrate static risk factors that represent enduring vulnerabilities, dynamic risk factors that fluctuate over time and are amenable to intervention, and protective factors that mitigate risk. No validated instrument can definitively predict which individual patient will attempt or die by suicide, making the clinical formulation of risk a process of synthesizing multiple data points into an overall risk estimate that guides clinical decision-making.

Static risk factors for suicide represent unchangeable demographic and historical variables that establish baseline vulnerability. Male sex confers a higher rate of completed suicide, with males dying by suicide at approximately three to four times the rate of females, though females attempt suicide at approximately three times the rate of males. Increasing age is associated with rising completed suicide rates, with elderly white males having the highest per-capita rate. Prior suicide attempt is the single strongest predictor of future suicide, with the risk highest in the year following an attempt. Family history of suicide and personal history of psychiatric diagnosis, particularly mood disorders, psychotic disorders, substance use disorders, and borderline personality disorder, are established risk factors. Access to firearms is a critical risk factor because firearms are the most lethal method and account for approximately half of all suicide deaths in the United States.

Dynamic risk factors fluctuate over time and represent the modifiable targets of clinical intervention. Current suicidal ideation must be characterized by its frequency, intensity, duration, and the degree to which the patient can control the thoughts. The presence of a specific suicide plan, including identification of method, availability of means, and the specificity and lethality of the plan, substantially increases acute risk. Intent to act, distinguished from passive wishes to die, represents the patient's determination to carry out a suicidal plan. Hopelessness, the belief that one's situation is intolerable and will not improve, is one of the strongest psychological predictors of suicide. Acute intoxication lowers inhibition and impairs judgment, and a substantial proportion of individuals who die by suicide have detectable blood alcohol or drug levels. Recent loss, humiliation, or interpersonal crisis can serve as proximal triggers that precipitate suicidal action in the context of chronic vulnerability.

Protective factors serve to buffer against suicidal behavior and should be actively assessed and reinforced. Strong social connectedness, including meaningful relationships with family, friends, and community, reduces suicide risk by providing sources of support, belonging, and reasons for living. Children in the home have been identified as a protective factor, particularly for women. Religious or spiritual beliefs that proscribe suicide may serve as a deterrent. Engagement in mental health treatment reflects both willingness to seek help and access to professional support. The capacity to identify reasons for living reflects a future orientation and valued connections that counterbalance suicidal despair. Fear of death or the physical pain of dying can inhibit suicidal action even in the presence of strong ideation. Restricted access to lethal means is one of the most effective protective interventions, as means restriction reduces suicide rates without full substitution of alternative methods.

<image>Panel A: Epidemiology of suicide showing annual mortality, ranking among causes of death by age group, male-to-female ratio for completions and attempts, and high-risk demographic groups. Panel B: Static risk factor assessment showing prior attempt as strongest predictor, male sex, increasing age, family history, psychiatric diagnosis, and firearm access with their relative risk contributions. Panel C: Dynamic risk factor evaluation showing ideation characterization across frequency, intensity and duration, plan specificity and lethality assessment, intent determination, hopelessness, acute intoxication, and proximal triggers. Panel D: Protective factor assessment showing social connectedness, children in home, religious beliefs, treatment engagement, reasons for living, and means restriction as the most effective preventive intervention.</image>

### Section 2: Suicide Risk Stratification and Management

Risk stratification organizes the clinical assessment into actionable levels that guide treatment planning and disposition decisions. Low risk is characterized by passive ideation without plan, intent, or recent attempt, with multiple protective factors and engagement in treatment. Moderate risk involves active ideation with a general plan but without specific means or current intent to act, with some protective factors and ambivalence about dying. High risk is defined by active ideation with a specific plan, available means, expressed intent, and few protective factors, often in the context of recent attempt, acute substance use, or psychosocial crisis. Imminent risk describes patients who are actively suicidal with strong intent and available means, requiring immediate intervention including constant observation and potential hospitalization. These categories are not rigid but serve as a framework for organizing clinical thinking and communicating risk level to other providers.

Safety planning is a collaborative intervention that provides patients with a structured, personalized set of coping strategies and resources to use during suicidal crises. The Stanley-Brown Safety Plan follows a six-step hierarchical structure: recognizing personal warning signs that a crisis may be developing; identifying internal coping strategies that the individual can use without contacting others, such as distraction activities and relaxation techniques; identifying people and social settings that can provide distraction from suicidal thoughts; listing specific individuals the patient can contact for support during a crisis; listing professional and crisis resources including the 988 Suicide and Crisis Lifeline, local crisis services, and emergency departments; and reducing access to lethal means. The safety plan differs fundamentally from a no-suicide contract, which has no evidence of effectiveness and creates a false sense of security. Safety plans should be documented in the medical record, provided to the patient in a portable format, and revisited regularly.

Means restriction is the most evidence-based suicide prevention strategy and should be discussed with every patient identified as at risk. Firearm access should be directly assessed, as firearms account for approximately half of all suicide deaths and have a case fatality rate exceeding eighty-five percent, making them the most lethal commonly available means. Counseling on safe storage, which involves storing firearms locked, unloaded, and separate from ammunition, or temporarily transferring firearms out of the home, is an intervention that can be delivered in clinical settings. Medication access should be evaluated, with potentially lethal medications such as opioids, benzodiazepines, and lithium prescribed in limited quantities or safeguarded by a responsible family member. Bridge barriers and other environmental means restriction measures have demonstrated effectiveness in reducing suicide at specific locations. Lethal means counseling should involve family members and support persons who can assist in implementing means restriction.

Disposition decisions for suicidal patients depend on the assessed level of risk, the patient's clinical status, and the availability of support and follow-up. Outpatient management is appropriate for patients at low to moderate risk who have adequate social support, are willing to engage in safety planning, have restricted access to lethal means, and can reliably access follow-up care. Intensive outpatient or partial hospitalization programs provide a higher level of structure and monitoring for patients at moderate risk who do not require twenty-four-hour supervision. Psychiatric hospitalization is indicated for patients at high or imminent risk, and may be pursued voluntarily when the patient agrees to admission or involuntarily when the patient meets legal criteria for danger to self and refuses voluntary treatment. Regardless of disposition, the clinical rationale for the level of care decision should be thoroughly documented, including the risk and protective factors considered, the interventions implemented, and the plan for follow-up.

<image>Panel A: Risk stratification levels showing low, moderate, high, and imminent risk categories with defining features of ideation, plan, intent, protective factors, and recommended clinical actions. Panel B: Stanley-Brown Safety Plan six-step hierarchy from warning sign recognition through internal coping, social contacts, help contacts, professional resources, and means restriction with documentation requirements. Panel C: Means restriction strategies showing firearm safe storage counseling, medication access limitation, environmental barriers, and family involvement with evidence for effectiveness in reducing suicide rates. Panel D: Disposition decision algorithm showing outpatient, intensive outpatient, and inpatient pathways based on risk level, social support, treatment engagement, means access, and documentation requirements.</image>

### Section 3: Acute Agitation Assessment

Acute agitation is a state of excessive motor activity, emotional arousal, and impaired behavioral control that represents one of the most common psychiatric emergencies encountered in emergency departments and inpatient settings. The clinical presentation ranges from psychomotor restlessness and irritability on the mild end to verbal aggression, physical aggression, and frank violence on the severe end. Rapid assessment is required because agitation can escalate quickly and poses risks to the patient, staff, and other patients, while simultaneously the underlying cause may represent a medical or psychiatric emergency requiring urgent treatment. The primary goals of managing acute agitation are to ensure the safety of all individuals in the environment, to identify and treat the underlying cause, and to help the patient regain behavioral control with the least restrictive intervention necessary.

The differential diagnosis of acute agitation is broad and must systematically consider medical, substance-related, and primary psychiatric etiologies. Medical causes that must be excluded include delirium from any cause, including infection, metabolic derangement, hypoxia, and intracranial pathology; hypoglycemia; thyroid storm; and medication toxicity or adverse drug reactions. Substance-related causes encompass intoxication with stimulants, phencyclidine, synthetic cannabinoids, or alcohol, as well as withdrawal from alcohol, benzodiazepines, or opioids. Primary psychiatric causes include psychotic disorders with paranoia or command hallucinations, manic episodes, severe anxiety including panic attacks, personality disorders with emotional dysregulation, and dissociative states. A focused physical examination including vital signs, neurological assessment, and mental status examination is essential, along with targeted laboratory testing including glucose, electrolytes, complete blood count, toxicology screen, and thyroid function when indicated.

De-escalation is the first-line approach to managing acute agitation and should be attempted before considering pharmacological or physical interventions. Environmental modifications include reducing stimulation by moving the patient to a quieter area, removing potential weapons or objects that could be thrown, and ensuring adequate space between the patient and staff. The clinician should maintain a calm, confident, and non-threatening demeanor, speaking slowly and in a low tone while avoiding direct eye contact that could be perceived as confrontational. Active listening and empathic validation communicate that the clinician understands the patient's distress and wants to help. Clear, simple communication avoids jargon and uses short sentences that are easier for an agitated individual to process. Offering choices within safe parameters, such as the option of oral medication or a preferred beverage, gives the patient a sense of autonomy and control. Setting limits should be done respectfully but firmly, communicating what behavior is expected while conveying the desire to help the patient feel better.

Staff safety protocols are essential components of agitation management and must be established and rehearsed before emergencies arise. A show of support, in which multiple trained staff members are present in a visible but non-threatening manner, communicates to the agitated patient that the situation is controlled and may itself reduce escalation. Clinicians should position themselves between the patient and the exit, maintaining an unobstructed escape route, and should never turn their back on an agitated patient or enter a room alone with a patient at risk of violence. Hands should be visible and relaxed, and clothing or accessories that could be grabbed should be secured. The assessment of imminent violence risk includes signs such as clenched fists, pacing, loud vocalizations, verbal threats, and a fixed or hostile stare. When violence appears imminent despite de-escalation attempts, the clinician should call for assistance and prepare for pharmacological intervention or, as a last resort, physical restraint.

<image>Panel A: Acute agitation spectrum showing mild psychomotor restlessness through moderate verbal aggression to severe physical aggression with assessment urgency and management goals at each level. Panel B: Differential diagnosis of acute agitation organized by medical causes including delirium and hypoglycemia, substance causes including intoxication and withdrawal, and psychiatric causes including psychosis and mania with required workup. Panel C: De-escalation technique protocol showing environmental modifications, clinician demeanor and positioning, active listening and empathic validation, clear communication, choice-offering, and respectful limit-setting. Panel D: Staff safety protocol showing show of support positioning, escape route maintenance, visible relaxed hands, violence risk indicators, and escalation pathway from de-escalation to pharmacological intervention to physical restraint.</image>

### Section 4: Pharmacological Management of Agitation

Oral medication should be offered first whenever the patient is willing and able to accept it, as voluntary oral medication preserves the patient's autonomy, avoids the trauma of involuntary injection, and supports the therapeutic relationship. First-line oral options include oral risperidone at two milligrams or oral olanzapine at five to ten milligrams for psychosis-related agitation, and oral lorazepam at one to two milligrams for agitation associated with anxiety, substance withdrawal, or when the etiology is unclear. A combination approach using both an antipsychotic and a benzodiazepine may provide synergistic calming effects with lower doses of each agent. Rapidly dissolving formulations of risperidone and olanzapine are available and may be preferred for patients who are willing to accept oral medication but whose reliability of swallowing a standard tablet is uncertain. Oral haloperidol at two to five milligrams remains an effective option and is particularly useful when intramuscular administration may be needed subsequently.

Intramuscular medication is indicated when oral medication has been refused or is inadequate and the patient's level of agitation poses a risk of harm. For psychosis-related agitation, intramuscular haloperidol at five milligrams combined with intramuscular lorazepam at two milligrams and intramuscular diphenhydramine at fifty milligrams, a combination colloquially known as the B52 cocktail, is a widely used and effective regimen. Intramuscular olanzapine at ten milligrams is an alternative that provides rapid sedation but should not be combined with intramuscular benzodiazepines due to the risk of respiratory depression and cardiovascular compromise. Intramuscular ziprasidone at ten to twenty milligrams offers an alternative with less sedation and no concurrent benzodiazepine restriction. For agitation of unknown etiology or in the setting of substance intoxication where the specific substance is unclear, intramuscular lorazepam at two milligrams is the safest initial choice because benzodiazepines lack the extrapyramidal and cardiovascular risks of antipsychotics. Intramuscular midazolam provides rapid onset but short duration and is useful when very quick behavioral control is needed.

The choice of pharmacological agent must account for the suspected etiology of agitation and the patient's medical status. In alcohol withdrawal, benzodiazepines are both the treatment of choice for withdrawal symptoms and effective for agitation management, while antipsychotics should be used cautiously because they lower the seizure threshold and could precipitate withdrawal seizures. In stimulant intoxication, benzodiazepines are preferred because the agitation results from excessive catecholaminergic and serotonergic activity, and antipsychotics may worsen hyperthermia or, in the case of low-potency agents, lower the blood pressure. In the elderly patient, lower doses must be used due to increased sensitivity, and antipsychotics should be used with particular caution given the FDA black box warning regarding increased mortality with antipsychotic use in elderly patients with dementia. In pregnancy, the risks and benefits of each agent must be weighed, with lorazepam generally considered the safer option when pharmacological management is necessary.

Physical restraint represents the most restrictive intervention and should be employed only when less restrictive measures have failed and the patient poses an immediate risk of harm to self or others. Restraint application requires trained personnel following an established institutional protocol, with a minimum of five staff members assigned to specific limb and head control positions. The patient must be placed in a supine position, as prone positioning increases the risk of positional asphyxia. Continuous monitoring of the restrained patient includes respiratory status, circulation in restrained limbs, hydration, toileting needs, and ongoing assessment of readiness for de-escalation. Regular reassessment, typically every one to two hours, is required by most state regulations and institutional policies, and the restraint order must be renewed within specified time intervals. Debriefing after the event should include both staff and patient, reviewing the circumstances that led to restraint, exploring alternative strategies for future situations, and addressing the psychological impact on all parties involved.

<image>Panel A: Oral medication first-line approach showing risperidone and olanzapine for psychotic agitation, lorazepam for non-psychotic agitation, combination strategies, rapidly dissolving formulations, and voluntary administration benefits. Panel B: Intramuscular medication options showing the B52 combination of haloperidol, lorazepam, and diphenhydramine, olanzapine monotherapy with benzodiazepine restriction, ziprasidone alternative, and lorazepam for unknown etiology. Panel C: Etiology-specific agent selection showing benzodiazepine preference in alcohol withdrawal and stimulant intoxication, dose reduction in elderly patients with dementia mortality warning, and pregnancy risk-benefit considerations. Panel D: Physical restraint protocol showing team composition and roles, supine positioning requirement, continuous monitoring parameters, reassessment intervals, order renewal requirements, and post-event debriefing for staff and patient.</image>

### Section 5: Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome is a rare but potentially fatal adverse reaction to dopamine-blocking medications, primarily antipsychotics, with mortality rates historically reported at ten to twenty percent though improved recognition and management have reduced this figure. The syndrome typically develops within the first two weeks of antipsychotic initiation or dose increase, though it can occur at any point during treatment. First-generation antipsychotics, particularly high-potency agents such as haloperidol, carry the highest risk, but NMS has been reported with virtually all antipsychotic medications including second-generation agents and even antiemetics such as metoclopramide. Risk factors include rapid dose escalation, use of high-potency agents, intramuscular administration, dehydration, agitation, and prior episodes of NMS, which confer a recurrence risk of approximately thirty percent upon rechallenge.

The clinical presentation of neuroleptic malignant syndrome is characterized by four cardinal features that typically develop over one to three days. Hyperthermia, often exceeding 40 degrees Celsius, results from impaired central thermoregulation due to dopaminergic blockade in the hypothalamus combined with increased heat generation from muscle rigidity. Lead-pipe muscular rigidity, a severe generalized increase in muscle tone that does not vary with the rate of passive movement, is the hallmark motor finding and reflects extreme extrapyramidal dysfunction. Autonomic instability manifests as tachycardia, labile or elevated blood pressure, diaphoresis, and tachypnea. Altered mental status ranges from agitation and confusion to obtundation and coma. The temporal evolution of symptoms often follows a characteristic sequence beginning with mental status changes and rigidity, followed by hyperthermia and autonomic instability, though the full syndrome may not develop in all cases.

Laboratory findings in neuroleptic malignant syndrome reflect the systemic consequences of sustained muscular rigidity and hyperthermia. Creatine kinase elevation is the most characteristic laboratory abnormality, often reaching levels greater than one thousand international units per liter and frequently exceeding ten thousand. This massive elevation results from rhabdomyolysis, the breakdown of striated muscle, which also produces myoglobinuria that can lead to acute renal failure. Leukocytosis, typically in the range of ten thousand to thirty thousand white blood cells per microliter, is common and should not be attributed to infection without appropriate evaluation. Hepatic transaminase elevations reflect hepatic injury from hyperthermia and hemodynamic compromise. Metabolic acidosis may develop secondary to sustained muscle activity and tissue hypoperfusion. The differential diagnosis includes serotonin syndrome, malignant hyperthermia, lethal catatonia, heatstroke, and central nervous system infection, each requiring specific evaluation and treatment.

Management of NMS requires immediate discontinuation of all antipsychotic medications and aggressive supportive care. Intravenous fluid resuscitation is critical to maintain renal perfusion in the setting of rhabdomyolysis and to prevent acute renal failure. Active cooling measures including cooling blankets, ice packs, and intravenous chilled saline should be employed to reduce core body temperature. Dantrolene, a direct-acting skeletal muscle relaxant that blocks calcium release from the sarcoplasmic reticulum, is used for severe hyperthermia and rigidity at doses of one to two-point-five milligrams per kilogram intravenously. Bromocriptine, a dopamine agonist administered at two-point-five milligrams three times daily, addresses the underlying dopaminergic blockade and may hasten recovery. Benzodiazepines can be used for muscle relaxation and agitation. Monitoring should include continuous cardiac monitoring, serial creatine kinase levels, renal function, and urine output. Electroconvulsive therapy has been used successfully in refractory cases and in cases where NMS transitions into or is difficult to distinguish from lethal catatonia.

<image>Panel A: NMS epidemiology and risk factors showing incidence with antipsychotic use, first-generation versus second-generation risk, high-potency agents, rapid dose escalation, dehydration, and thirty percent recurrence risk. Panel B: Cardinal features of NMS showing hyperthermia exceeding 40 degrees Celsius, lead-pipe rigidity, autonomic instability with tachycardia and labile blood pressure, and altered mental status with typical temporal evolution sequence. Panel C: Laboratory findings showing creatine kinase elevation greater than 1000 with rhabdomyolysis mechanism, leukocytosis, hepatic transaminase elevation, metabolic acidosis, and differential diagnosis including serotonin syndrome and malignant hyperthermia. Panel D: NMS management protocol showing antipsychotic discontinuation, intravenous fluid resuscitation, active cooling, dantrolene dosing for rigidity, bromocriptine for dopamine agonism, and ECT for refractory cases.</image>

### Section 6: Serotonin Syndrome

Serotonin syndrome is a potentially life-threatening condition resulting from excessive serotonergic activity in the central and peripheral nervous systems, most commonly caused by pharmacological interactions between serotonergic medications. The onset is typically acute, developing within hours of a change in medication, dose increase, or addition of a serotonergic agent. The most dangerous precipitating combinations involve monoamine oxidase inhibitors with serotonin reuptake inhibitors or other serotonergic agents, which can produce fulminant serotonin syndrome with significant mortality. Other common combinations include SSRIs with tramadol, SSRIs with triptans, SSRIs with dextromethorphan, and the concurrent use of multiple serotonergic antidepressants. Recreational drugs including MDMA, methamphetamine, and synthetic cathinones can also produce serotonin syndrome, as can herbal preparations such as St. John's wort in combination with serotonergic medications.

The clinical presentation of serotonin syndrome involves a triad of neuromuscular hyperactivity, autonomic dysfunction, and altered mental status. Neuromuscular findings are the most diagnostically specific and include clonus, particularly lower extremity clonus which may be spontaneous, inducible, or ocular; hyperreflexia; myoclonus; tremor; and muscular rigidity in severe cases. Autonomic features include hyperthermia, tachycardia, hypertension or labile blood pressure, diaphoresis, mydriasis, and diarrhea. Mental status changes range from anxiety, agitation, and restlessness in mild cases to delirium, confusion, and obtundation in severe presentations. The Hunter Serotonin Toxicity Criteria provide a validated diagnostic algorithm that requires the presence of a serotonergic agent plus clonus, inducible or spontaneous, combined with any of the other features, and this clinical diagnostic approach is more sensitive and specific than the original Sternbach criteria.

Distinguishing serotonin syndrome from neuroleptic malignant syndrome is a critical clinical skill because the two conditions have overlapping features but distinct causes and treatments. Serotonin syndrome develops rapidly, typically within hours of the precipitating pharmacological change, while NMS develops over days. The causative agents differ: serotonin syndrome results from serotonergic excess, while NMS results from dopaminergic blockade. Neuromuscular findings diverge importantly: serotonin syndrome produces hyperreflexia, clonus, and myoclonus reflecting neuromuscular excitability, while NMS produces lead-pipe rigidity reflecting extrapyramidal rigidity. Hyperthermia is present in both conditions but tends to be more extreme in NMS. Creatine kinase elevation is characteristic of NMS and may be absent or only mildly elevated in serotonin syndrome. Serotonin syndrome features prominent gastrointestinal symptoms including diarrhea that are not typically present in NMS. Both conditions require urgent treatment, but the management protocols differ substantially.

Management of serotonin syndrome begins with immediate discontinuation of all serotonergic medications and supportive care tailored to the severity of the presentation. Mild cases may require only observation and discontinuation of the offending agent, as serotonin syndrome is typically self-limiting and resolves within twenty-four to seventy-two hours once the serotonergic agent is eliminated. Moderate cases require active symptom management with benzodiazepines for agitation, tremor, and myoclonus, and intravenous fluids for hydration and temperature regulation. Severe cases with hyperthermia exceeding 41 degrees Celsius, cardiovascular instability, or severe rigidity require intensive care unit admission with aggressive cooling, intubation and neuromuscular paralysis if rigidity prevents adequate ventilation, and cyproheptadine, a serotonin antagonist, administered as a twelve-milligram loading dose followed by two milligrams every two hours until clinical improvement. Antipyretics are ineffective because the hyperthermia results from excessive muscle activity rather than a reset of the hypothalamic temperature set point.

<image>Panel A: Serotonin syndrome precipitants showing MAOI plus SSRI as most dangerous, other common drug combinations including tramadol, triptans, and dextromethorphan, recreational drug causes, and herbal supplement risks. Panel B: Clinical triad showing neuromuscular findings of clonus, hyperreflexia, and myoclonus; autonomic features of hyperthermia, tachycardia, and diaphoresis; and mental status changes from anxiety to delirium with Hunter Toxicity Criteria algorithm. Panel C: Serotonin syndrome versus NMS differentiation showing rapid versus gradual onset, serotonergic versus dopaminergic causation, hyperreflexia versus lead-pipe rigidity, CK levels, gastrointestinal symptoms, and management divergence. Panel D: Severity-based management showing observation for mild cases, benzodiazepines and fluids for moderate cases, and ICU admission with cooling, paralysis, and cyproheptadine twelve-milligram loading dose for severe cases.</image>

### Section 7: Catatonia

Catatonia is a neuropsychiatric syndrome characterized by a cluster of motor, behavioral, and autonomic abnormalities that can occur in the context of psychiatric, medical, or neurological conditions. The syndrome has been reconceptualized in the DSM-5 as a specifier that can be applied to multiple disorders rather than a subtype exclusively associated with schizophrenia. The DSM-5 requires the presence of three or more of twelve defined features for diagnosis. Recognition of catatonia is clinically critical because it is common, affecting approximately ten percent of acute psychiatric inpatients, is frequently underdiagnosed, and requires specific treatment that differs markedly from the management of the underlying condition.

The twelve DSM-5 features of catatonia include both hyperkinetic and hypokinetic manifestations. Stupor refers to minimal psychomotor activity with absent responsiveness to the environment despite apparent wakefulness. Catalepsy is the passive maintenance of postures imposed by the examiner against gravity, sometimes for prolonged periods. Waxy flexibility describes a slight, even resistance to repositioning by the examiner, giving a wax-like quality to passive movement. Mutism is absent or minimal verbal responsiveness. Negativism manifests as opposition or absent response to external stimuli or instructions. Posturing is the active, spontaneous maintenance of abnormal positions against gravity. Mannerism involves odd, purposeful movements performed in an exaggerated or stylized manner. Stereotypy consists of repetitive, non-goal-directed movements. Agitation occurs without apparent external provocation and is not influenced by external stimuli. Grimacing involves fixed facial expressions that are maintained inappropriately. Echolalia is the mimicking of another person's speech. Echopraxia is the mimicking of another person's movements.

The etiology of catatonia extends far beyond psychiatric conditions and includes a broad range of medical and neurological causes that must be systematically evaluated. Among psychiatric conditions, mood disorders, particularly bipolar disorder, are actually a more common cause of catatonia than schizophrenia, contrary to historical assumptions. Medical causes include autoimmune encephalitis, particularly anti-NMDA receptor encephalitis which has emerged as an important and treatable cause; metabolic disturbances including hepatic encephalopathy, hypercalcemia, and hyponatremia; neurological conditions including stroke, seizures, and space-occupying lesions; infections including encephalitis and HIV; and medication-related causes including antipsychotic-induced catatonia. The workup for new-onset catatonia should include comprehensive metabolic panel, thyroid function, creatine kinase, urinalysis, toxicology screen, brain imaging, and consideration of lumbar puncture and autoimmune antibody testing.

The treatment of catatonia relies primarily on benzodiazepines and electroconvulsive therapy. The lorazepam challenge test serves as both a diagnostic and therapeutic intervention: administration of one to two milligrams of intravenous or intramuscular lorazepam produces marked improvement in catatonic symptoms within minutes to hours in approximately sixty to eighty percent of cases, strongly supporting the diagnosis. Ongoing treatment with scheduled lorazepam at doses ranging from six to twenty-four milligrams daily may be required, with gradual titration to effect. Electroconvulsive therapy is the most effective treatment for catatonia and is indicated when benzodiazepines produce an insufficient response, when the presentation is severe or life-threatening as in malignant catatonia with hyperthermia and autonomic instability, or when the underlying cause requires rapid resolution. Antipsychotic medications should be used with extreme caution in catatonia because they may worsen the syndrome and increase the risk of progression to malignant catatonia or neuroleptic malignant syndrome, which shares pathophysiological features with catatonia. The Bush-Francis Catatonia Rating Scale provides a standardized tool for quantifying symptom severity and monitoring treatment response.

<image>Panel A: Catatonia definition showing DSM-5 reconceptualization as a specifier across disorders, prevalence of ten percent in acute psychiatric inpatients, underdiagnosis, and requirement for three of twelve features. Panel B: Twelve DSM-5 catatonia features organized as hypokinetic including stupor, catalepsy, waxy flexibility, mutism, negativism, and posturing, and hyperkinetic including mannerism, stereotypy, agitation, grimacing, echolalia, and echopraxia. Panel C: Catatonia etiology showing mood disorders as the most common psychiatric cause, autoimmune encephalitis as an important medical cause, metabolic, neurological, and medication-related causes with recommended diagnostic workup. Panel D: Catatonia treatment showing lorazepam challenge test with sixty to eighty percent response rate, maintenance benzodiazepine dosing, ECT for refractory and malignant cases, antipsychotic caution, and Bush-Francis Rating Scale monitoring.</image>

### Section 8: Other Psychiatric Emergencies

Acute psychosis with dangerousness represents a psychiatric emergency when the patient's reality testing is severely impaired and their behavior poses a risk of harm to self or others. Command auditory hallucinations instructing the patient to harm themselves or others are a particularly high-risk presentation, though not all patients who experience command hallucinations act on them. Paranoid delusions may lead to preemptive violence when the patient perceives imminent threat from specific individuals. First-episode psychosis presents unique challenges because the patient has no established treatment history, the underlying diagnosis is uncertain, and the experience of psychosis and subsequent psychiatric intervention can be profoundly traumatic. Acute management includes establishing safety, administering antipsychotic medication with the patient's consent when possible and involuntarily when legally justified, and conducting a thorough medical evaluation to exclude organic causes of psychosis including substance intoxication, delirium, and autoimmune or infectious encephalitis.

Severe alcohol withdrawal represents a medical emergency with significant morbidity and mortality. The Clinical Institute Withdrawal Assessment for Alcohol scale provides a standardized tool for quantifying withdrawal severity across ten domains including nausea, tremor, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, orientation, and clouding of sensorium. Withdrawal seizures typically occur twelve to forty-eight hours after the last drink and are generalized tonic-clonic in nature. Delirium tremens, the most severe manifestation, develops in approximately three to five percent of patients in withdrawal, typically between forty-eight and seventy-two hours after the last drink, and presents with fluctuating consciousness, severe autonomic hyperactivity, visual and tactile hallucinations, and agitation, with a mortality rate of up to thirty-seven percent without treatment. Benzodiazepine administration using either a symptom-triggered protocol guided by CIWA scores or a fixed-dose tapering schedule is the standard treatment, with diazepam or chlordiazepoxide preferred for their long half-lives and smooth withdrawal trajectory.

Panic attacks and acute dissociative episodes frequently present to emergency departments and require differentiation from medical emergencies. Acute panic attacks produce overwhelming fear accompanied by intense somatic symptoms including palpitations, chest pain, dyspnea, paresthesias, dizziness, and feelings of unreality, which can convincingly mimic acute coronary syndrome, pulmonary embolism, or other medical emergencies. Appropriate medical evaluation must be conducted before attributing symptoms to panic, particularly in patients without a prior history of panic disorder. Acute dissociative episodes, including dissociative fugue, depersonalization-derealization episodes, and conversion symptoms with functional neurological presentations, may present with dramatic symptoms including amnesia, paralysis, or altered consciousness that require neurological evaluation. Compassionate, non-dismissive management is essential for both presentations, and emergency treatment includes benzodiazepines for severe panic and reassurance, grounding techniques, and safety assessment for dissociative episodes.

Eating disorder medical emergencies require recognition of the physiological complications that can produce acute, life-threatening decompensation. Severe malnutrition in anorexia nervosa can produce bradycardia, hypotension, hypothermia, and electrolyte abnormalities, any of which may require medical stabilization before psychiatric treatment can be initiated. Refeeding syndrome is a potentially fatal metabolic complication that occurs when nutrition is reintroduced too rapidly in severely malnourished patients, producing shifts in phosphorus, potassium, and magnesium that can cause cardiac arrhythmias, heart failure, delirium, and death. Purging behaviors in bulimia nervosa can produce hypokalemia with associated cardiac arrhythmias, metabolic alkalosis, esophageal tears, and dental erosion. Ipecac abuse and laxative abuse carry additional specific medical risks. The clinical team must assess the medical stability of patients with eating disorders presenting in crisis and determine whether medical hospitalization, psychiatric hospitalization, or both are required.

<image>Panel A: Acute psychosis with dangerousness showing command hallucination risk, paranoid delusion violence pathway, first-episode psychosis challenges, and management priorities including safety, medication, and organic cause exclusion. Panel B: Alcohol withdrawal timeline showing symptom onset at six to twelve hours, seizure risk at twelve to forty-eight hours, delirium tremens at forty-eight to seventy-two hours with CIWA-guided benzodiazepine treatment protocol. Panel C: Emergency presentations showing panic attack versus medical emergency differentiation, dissociative episode presentations, medical evaluation requirements, and compassionate management approaches for both conditions. Panel D: Eating disorder medical emergencies showing anorexia nervosa physiological complications, refeeding syndrome electrolyte shifts and cardiac risks, purging complications in bulimia nervosa, and medical stabilization assessment criteria.</image>

### Section 9: Involuntary Treatment

Involuntary psychiatric hospitalization is governed by state-specific civil commitment laws that establish the criteria and procedures under which individuals may be detained for psychiatric evaluation and treatment against their will. The fundamental legal standard across most jurisdictions requires that the individual has a mental illness and, as a result of that illness, poses a danger to self or others, or is gravely disabled, meaning unable to provide for basic needs including food, clothing, and shelter. The initial psychiatric hold, often termed an emergency detention or involuntary evaluation, typically permits detention for a limited period, commonly seventy-two hours, during which the patient must be evaluated and either discharged, converted to voluntary status, or brought before a judicial hearing for extended commitment. The legal threshold for continued commitment beyond the initial hold is generally higher and requires clear and convincing evidence presented at a hearing before a judge or magistrate.

The concepts of decision-making capacity and competence are distinct but frequently confused in clinical practice. Capacity is a clinical determination made by a treating physician regarding a patient's ability to make a specific medical decision at a specific point in time, and the four components that must be assessed are the ability to understand the relevant information, the ability to appreciate how the information applies to one's own situation, the ability to reason about treatment options using the information to weigh risks and benefits, and the ability to express a consistent choice. Competence, by contrast, is a legal determination made by a court that applies globally to an individual's ability to manage their affairs. A patient may be found to lack capacity for a specific treatment decision while retaining capacity for other decisions, and capacity can fluctuate over time with changes in clinical status. When a patient is determined to lack capacity, a surrogate decision-maker is identified according to the state's hierarchy of authority, typically following the order of healthcare proxy, spouse, adult children, parents, and siblings.

Involuntary medication administration represents one of the most contentious areas at the intersection of psychiatry and law. In emergency situations involving imminent danger to self or others, most jurisdictions permit the administration of medication without the patient's consent under emergency authority, which is time-limited and applies only to the acute crisis. For non-emergency situations in which a hospitalized patient refuses medication but is deemed to lack capacity to make treatment decisions, legal procedures vary by jurisdiction. Some states authorize an administrative review process within the hospital, while others require a court hearing to authorize involuntary medication. The clinician must document the clinical rationale for involuntary medication, the specific danger or harm that treatment is intended to address, the least restrictive treatment alternative, and the efforts made to obtain the patient's voluntary agreement.

Ethical tensions in psychiatric emergency practice require thoughtful navigation of competing principles. Beneficence obligates the clinician to act in the patient's best interest and to provide treatment that alleviates suffering and prevents harm. Autonomy demands respect for the patient's right to make decisions about their own treatment, even when those decisions conflict with clinical recommendations. Non-maleficence requires that treatment interventions, including involuntary detention and medication, do not cause harm disproportionate to their benefit. Justice demands that involuntary treatment standards are applied equitably across populations and that socioeconomic, racial, and cultural factors do not inappropriately influence commitment decisions. The therapeutic relationship must be maintained or repaired after involuntary interventions, which requires transparent communication about the reasons for the intervention, acknowledgment of the patient's perspective, and collaborative treatment planning as the patient's clinical status permits.

<image>Panel A: Involuntary hospitalization criteria showing mental illness plus danger to self, danger to others, or grave disability across jurisdictions with seventy-two-hour initial hold and judicial hearing requirements. Panel B: Capacity assessment four-component model showing understanding, appreciation, reasoning, and expression of choice with clinical versus legal competency distinction and surrogate decision-maker hierarchy. Panel C: Involuntary medication framework showing emergency authority for imminent danger, non-emergency judicial or administrative review procedures, and required clinical documentation elements. Panel D: Ethical tension navigation showing beneficence-autonomy balance, non-maleficence proportionality requirement, justice in equitable standards application, and post-intervention therapeutic relationship repair strategies.</image>

### Section 10: Documentation and Risk Management

Documentation in psychiatric emergencies serves critical clinical, communication, and medicolegal functions and must meet a higher standard of specificity and thoroughness than routine clinical notes. Every suicide risk assessment should document the specific risk factors identified and their current status, protective factors present, the patient's own statements about suicidal ideation including direct quotes when relevant, the overall risk formulation with a clinically supported rationale, and the specific interventions implemented including safety planning, means restriction counseling, and disposition decision. The reasoning process that led to the clinical decision should be transparent in the documentation, showing that the clinician considered the relevant factors and reached a defensible conclusion, even when the outcome is uncertain or the risk level is moderate.

Risk management principles in psychiatric emergency practice are designed to minimize adverse outcomes and to demonstrate that the standard of care was met when adverse events do occur. The standard of care does not require that a clinician predict suicide or prevent all adverse outcomes, as these are impossible standards, but rather that the clinician perform and document a reasonable assessment and implement appropriate interventions based on the findings. Foreseeable risk should be identified and addressed, which means that known risk factors should be assessed and that modifiable risk factors should be the target of intervention. Communication of risk between providers, including during transitions of care such as shift changes, discharges, and transfers between units, must be clear and complete, with specific documentation of risk level, ongoing concerns, and recommended monitoring.

Transitions of care represent particularly high-risk periods for suicidal patients and require specific attention and protocols. The period immediately following discharge from psychiatric hospitalization is associated with markedly elevated suicide risk, with the first week and especially the first seventy-two hours after discharge carrying the highest per-day risk of suicide in the entire illness trajectory. Discharge safety planning should include identification of outpatient follow-up within seven days of discharge, provision of a written safety plan, means restriction confirmation, twenty-four-hour crisis contact information, and a warm handoff to the outpatient provider when possible. Emergency department to outpatient transitions for patients who are assessed and released from the emergency department require similar attention to follow-up scheduling and safety planning. Between-provider handoffs during shift changes should include explicit communication of each patient's risk level, recent clinical changes, and monitoring requirements.

Quality improvement in psychiatric emergency care involves systematic review of adverse events, near-misses, and clinical processes to identify opportunities for enhancing patient safety. Root cause analysis of completed suicides examines the systems-level factors that contributed to the outcome, including staffing patterns, observation protocols, environmental hazards, communication breakdowns, and treatment decisions. Psychological autopsy reconstructs the circumstances of a suicide through interviews with family members, review of medical records, and examination of the decedent's communications to identify risk factors that were present and to evaluate whether they were recognized and addressed. Clinician support programs are essential because the loss of a patient to suicide is one of the most distressing events in psychiatric practice, and affected clinicians may experience grief, guilt, anxiety, and questioning of their clinical judgment. Institutional support should include immediate peer support, access to formal debriefing, and guidance regarding legal and professional obligations.

<image>Panel A: Psychiatric emergency documentation requirements showing suicide risk assessment elements including risk factors, protective factors, patient statements, overall formulation, interventions, and clinical reasoning transparency. Panel B: Risk management principles showing standard of care definition, foreseeable risk identification and intervention, and communication requirements during transitions of care with documentation standards. Panel C: Transition of care protocols showing post-discharge elevated risk period, seven-day follow-up requirement, written safety plan provision, means restriction confirmation, warm handoff process, and shift change handoff communication elements. Panel D: Quality improvement showing root cause analysis of completed suicides, psychological autopsy methodology, clinician support programs for post-suicide grief, and institutional debriefing and support resources.</image>

---

## Summary

- Suicide risk assessment integrates static factors including prior attempts and male sex, dynamic factors including current ideation, plan, intent, and hopelessness, and protective factors including social connectedness and means restriction
- Safety planning using the Stanley-Brown six-step model is a collaborative, evidence-based intervention that replaces the ineffective no-suicide contract
- Means restriction, particularly regarding firearms, is the most evidence-based suicide prevention strategy and should be discussed with all at-risk patients
- Verbal de-escalation using empathic listening, calm demeanor, and choice-offering is the first-line approach for acute agitation before pharmacological intervention
- Pharmacological management of agitation follows a stepwise approach from oral medication to intramuscular agents, with agent selection guided by the suspected etiology
- Neuroleptic malignant syndrome presents with hyperthermia, lead-pipe rigidity, autonomic instability, and altered mental status and is treated with dantrolene and bromocriptine after antipsychotic discontinuation
- Serotonin syndrome presents with clonus, hyperreflexia, autonomic instability, and agitation and is treated with cyproheptadine after serotonergic medication discontinuation
- Catatonia requires three of twelve DSM-5 features and responds to the lorazepam challenge in sixty to eighty percent of cases, with ECT for refractory presentations
- Involuntary hospitalization requires mental illness plus danger to self, danger to others, or grave disability, with judicial review required for extended commitment
- The post-discharge period represents the highest-risk time for suicide, requiring seven-day follow-up, written safety plans, and means restriction confirmation

---

## Key Terms

| Term | Definition |
|------|------------|
| Safety plan | A collaborative, hierarchical set of coping strategies and resources for use during suicidal crises |
| Means restriction | The reduction of access to lethal methods of suicide, the most evidence-based prevention strategy |
| De-escalation | Verbal and environmental techniques used to reduce agitation before pharmacological intervention |
| NMS | Neuroleptic Malignant Syndrome; life-threatening reaction to dopamine-blocking agents with hyperthermia, rigidity, autonomic instability, and altered mental status |
| Serotonin syndrome | Excess serotonergic activity producing neuromuscular hyperactivity, autonomic dysfunction, and altered mental status |
| Catatonia | Neuropsychiatric syndrome of motor, behavioral, and autonomic abnormalities requiring three of twelve DSM-5 features |
| Capacity | Clinical determination of a patient's ability to understand, appreciate, reason about, and express a choice regarding a specific medical decision |
| Involuntary hold | Legal mechanism for detaining an individual with mental illness who poses danger to self or others or is gravely disabled |

---

*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*